Publication at First Faculty of Medicine |
2013
Abstract
Neuroendocrine neoplasias are represented by heterogenous gorup of tumours with very different clinical features. Correct diagnosis should be followed by correct specific treatment.
Today their therapy consist not only of surgery, local treatment of liver metastases and in certain cases of chemotherapy. We can see signoficant progress in targeted biological therapy including antiprolifferative effect of somatostatin analogues, thyrosin kinase inhibitors (TKI) and mTOR inhibitors (mammalian target of rapamycin).
Considerable advance was done also in treatment with radiolabelled somatostatin analogues PRRT).